Core Viewpoint - The collaboration between the Chinese Academy of Sciences and Guangxi marks a significant step in technology transfer and innovation, with a focus on addressing local industrial needs and enhancing economic growth through scientific advancements [9][15]. Group 1: Event Overview - The event organized by the Guangxi Science and Technology Department and the Chinese Academy of Sciences showcased 240 major technological achievements, resulting in 25 cooperation intentions and a total signing amount of 88.75 million yuan [8][9]. - The event featured 65 selected technological achievements across various fields, including new generation information technology, high-end equipment, and biomedicine, highlighting the role of technology in industrial upgrading [10][11]. Group 2: Collaboration Details - The partnership is characterized by a systematic and large-scale approach, with over 30 affiliated units of the Chinese Academy of Sciences participating, aiming to provide innovative support for Guangxi's industrial development [9][10]. - Specific projects signed include the development of anti-pollution technology and new materials, with a total investment of 50 million yuan, indicating a strong alignment between local industry needs and scientific research capabilities [13][14]. Group 3: Economic Impact - The collaboration is expected to generate new economic growth and productivity, with anticipated investments exceeding 500 million yuan from the cooperation intentions established during the event [14][15]. - Guangxi's technology transfer contracts have seen an average annual growth rate of 32% over the past three years, with a projected transaction volume exceeding 80 billion yuan in 2024 [15][16].

荣格个人护理 . 以下文章来源于荣格个人护理 ，作者荣格研讨会 MicroZenith@紫球藻提取物 抗皱,紧致,防晒,保湿、抗 氧化、抗菌、抗病毒 我司海洋微藻细胞培养的优势: 个人护理、美容、化妆品、香水、包装等行业专业人士必读，覆盖全球资讯，关注中国市场，荣格工业 传媒旗下《happi China 国际个人护理品生产商情》杂志，美国《happi》与《Beauty Packaging》杂志在 中国唯一合作伙伴。 在竞争激烈的美妆赛道中，美妆品牌如何走向差异化与高端化，这家微藻合成生物公司希望用新一代藻类提取物 （三角褐指藻提取物、紫球藻提取物、小球藻提取物）助力国产品牌走向高端化、国际化。 MicroZenith@小球藻提取物 抗皱,紧致,祛痘、舒缓、保 湿、抗氧化 1) 微藻活性物密度高5-10倍。海洋微藻一般难以采 用异养等高密度培养方法,但通过合成生物+光控培养 技术可以将微藻细胞密度和生物活性成分提高5-10倍。 2）微藻活性物高品质。传统的跑道池、管式反应器中 重金属或塑化剂的污染难以有效避免和控制，我司开 发了独家专利的新型生物反应器,有效解决污染问题。 3)无菌、无重金属、无农残,无核污染。 ...

Core Viewpoint - Zhejiang Rongrui Technology Co., Ltd. has completed nearly 100 million yuan in Pre-A round financing, which will primarily be used to accelerate product pipeline development and continue the industrialization and commercialization process [1] Company Overview - Founded in 2022, Rongrui Technology focuses on synthetic biology as its core technology, integrating the latest advancements in artificial intelligence to develop disruptive technologies for artificial life and functional molecules [2] - The company aims to achieve green biological manufacturing in areas such as health food ingredients and high-value chemicals, while also reducing product costs and improving quality [2] - The product pipeline includes dozens of successfully developed products, such as important industrial enzyme varieties (lipase, nitrile hydratase, nitrile hydrolase, amide enzyme), pharmaceuticals, pesticides, high-value fine chemicals (chiral alcohols, chiral amines, chiral non-natural amino acids, amide compounds), as well as health oils, new structural esters, vitamins, and sugar substitutes [2] - The company has established multiple collaborations with leading enterprises in its niche [2] Industry Event - The 4th Synthetic Biology and Green Biological Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the "1+4" theme: AI + Biological Manufacturing [3] - The conference will cover four major application areas: green chemicals and new materials, future food, future agriculture, and beauty raw materials, inviting international leading companies, representative industrial experts, government, parks, capital, associations, and alliances to explore the development trends of the biological manufacturing industry during the 14th Five-Year Plan [3] - The event aims to promote the transfer and transformation of scientific and technological achievements, product scaling, and talent acquisition [3]

SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 欢迎科研院所、企业报名！ 往期现场： 03 大会日程 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioC ...

Core Insights - Company reported a contradictory financial performance for 2024, with revenue of 2.178 billion yuan, a year-on-year increase of 12.37%, but a net profit of 190 million yuan, down 57.8% [2] - The company addressed key regulatory concerns regarding overseas revenue authenticity, sharp decline in gross margin, and abnormal inventory growth in a detailed response to the Shanghai Stock Exchange [2][3] Revenue and Market Performance - The company achieved overseas revenue exceeding 1 billion yuan for the first time, reaching 1.032 billion yuan, accounting for 47.39% of total revenue, with a year-on-year growth of 30.34% [3] - The European market was the primary source of overseas revenue, contributing 429 million yuan, while the Americas and Asia accounted for 294 million yuan and 309 million yuan, respectively [3] - The growth in revenue was primarily supported by the top five overseas customers, whose sales reached 418 million yuan, an increase of 111 million yuan from the previous year [3] Pricing Pressure and Gross Margin Decline - The company acknowledged significant price declines due to intensified market competition, particularly for L-valine, leading to a sharp drop in average selling prices for amino acids and vitamins [4][5] - The average selling price of amino acid products fell from 19,000 yuan per ton in 2023 to 15,600 yuan per ton in 2024, a decrease of 17.89%, while vitamin products saw a 54.09% drop from 84,300 yuan per ton to 38,700 yuan per ton [4] - The gross margin plummeted from 40.52% to 24.92%, a decline of 15.6 percentage points, raising concerns from the Shanghai Stock Exchange [4] Inventory and Financial Indicators - The company's inventory value surged to 407 million yuan, an increase of 80.09% year-on-year, attributed to increased stock of goods and raw materials [5][6] - Inventory turnover rate decreased from 6.37 times to 5.16 times, indicating a potential risk of impairment due to high inventory levels amid declining prices [5][6] Expansion and Future Projects - Despite the challenges, the company is aggressively expanding its production capacity, with construction projects valued at 1.592 billion yuan, including a 50,000-ton bio-based succinic acid project and a 50,000-ton bio-based propylene glycol project [7] - The company anticipates that these projects will begin operations in the second half of 2025, although there are concerns about the timely realization of benefits from these investments [8] Strategic Initiatives - The company is pursuing collaborations to enhance its supply chain, including forming a "Bio-based Polyester Textile Industry Alliance" and signing strategic agreements with BASF for product development [9] - Additionally, the company secured a 20-year exclusive license for the bio-based production of tryptophan technology from Eurobio [10]

Core Viewpoint - Rongrui Technology focuses on green manufacturing in fields such as industrial enzyme preparations, health foods, pharmaceutical chemicals, and functional new materials, leveraging synthetic biology and artificial intelligence to develop disruptive technologies for green bio-manufacturing [1][2]. Group 1: Company Overview - Rongrui Technology was established in 2022 and has successfully developed dozens of products, including key industrial enzyme varieties such as lipase and amide enzymes, as well as high-value fine chemicals and health products [1]. - The company has formed multiple collaborations with leading enterprises in its niche sectors [1]. Group 2: Recent Financing - Rongrui Technology recently completed nearly 100 million yuan in Pre-A round financing, led by PwC Capital and Dinghui VGC, with Kai Cheng Capital serving as the exclusive financial advisor [1]. - The funds raised will primarily be used to accelerate product pipeline development and continue the industrialization and commercialization processes [1]. Group 3: Management and Investor Insights - The CEO of Rongrui Technology expressed gratitude for the support from investors and emphasized the company's commitment to enhancing technology, production facilities, and commercial channels to ensure sustained growth [2]. - Investors from PwC Capital and Dinghui VGC highlighted the team's extensive industrial experience and solid R&D foundation, expressing confidence in the company's growth prospects and its ability to create social value through its strong technology platform [3].

美诺华 20250625 摘要 美诺华正推进创新益生菌药物 389 产品，该产品旨在通过调节肠道菌群， 实现降糖、减重等效果，计划以保健品形式在欧洲注册，并通过跨境电 商等方式进入国内市场，预计最快 2026 年第一季度实现商业化销售。 389 产品目前定位为非药产品，目标市场包括保健品、食品添加剂和新 食品成分。公司计划先通过保健品或新食品成分的审批，再进行小规模 临床试验，以反推产品的有效性，未来或将开发双靶或三靶药物。 389 产品在欧洲和美国市场的注册及上市时间进度方面，安全性实验预 计需要六个月时间，最早可能在 2026 年第一季度上市。在安全性实验 结束后，将以数据模型及佐证材料申报备案。 美诺华对 389 产品的市场空间估算主要基于两类人群：一是使用规划类 生物治疗药物后进入戒断期的人群，二是希望减肥但不愿意接受打针和 吃药的人群，预计前者市场规模可达 50~60 亿美元/年。 美诺华已对 J389 产品进行了深度专利保护，并已递交了专利申请，预计 两周内会获得专利号。公司与美国和欧洲合作方签订了许可协议，后续 在欧洲注册、安全性实验等费用均由合作方承担，美诺华享有约 8%的 收入分成。 Q&A ...

生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （ ...

Core Viewpoint - The article discusses the advancements in synthetic biology tools for customizing yeast cell factories, highlighting their potential in producing high-value compounds efficiently [3]. Group 1: Innovative Tools for Yeast Cell Factories - The paper titled "Innovative tools for customized yeast cell factory" outlines significant progress in synthetic biology tools, including genome editing, computational tools, adaptive laboratory evolution, and standardization of biological DNA components [3]. - These tools aim to provide practical guidelines for the effective development of customized yeast cell factories [3]. Group 2: Genome Editing Tools - Genome editing has evolved from single-gene editing to simultaneous multi-gene editing, with CRISPR-Cas systems enabling precise modifications in yeast genomes, including knockouts, insertions, and replacements [6]. - New variants of CRISPR-Cas, such as base editing and prime editing, allow for single nucleotide changes to alter gene functions [6]. Group 3: Computational Tools - Computational tools, including metabolic modeling and the integration of omics technologies, guide engineering strategies and expected flux adjustments [7]. - Genome-scale metabolic models (GEMs) have been widely applied in yeast metabolic engineering, with large-scale kinetic models playing a crucial role in designing and understanding metabolic reactions [7]. Group 4: Adaptive Laboratory Evolution - Adaptive laboratory evolution (ALE) is a powerful strategy for enhancing yeast strain performance by applying selective pressure over generations, leading to the emergence of more adaptive strains [8]. - Combining ALE with whole-genome sequencing helps identify beneficial mutations and provides insights into the genetic basis of adaptability [8]. Group 5: Standardization of Biological DNA Components - The increasing complexity of yeast cell factory designs necessitates precise control and regulation of biological components, gene circuits, or biological systems [9]. - Synthetic biology offers standardized biological components, allowing researchers to assemble these components into complex systems with predictable behaviors [9].

Core Viewpoint - The research team at Sichuan University is leveraging synthetic biology to develop a cost-effective production method for spermidine, a natural polyamine with significant applications in anti-aging and cardiovascular disease prevention, which is projected to become a billion-dollar bioactive molecule [2][3]. Group 1: Technology and Innovation - The production of spermidine has been hampered by high costs and technical bottlenecks, with traditional extraction methods yielding only 1% purity and chemical synthesis being prohibitively expensive [3][4]. - The team has utilized machine learning algorithms to simulate yeast metabolic networks, significantly enhancing spermidine synthesis efficiency [4]. - A breakthrough was achieved by discovering an extracellular secretion mechanism that allows spermidine to be actively expelled from cells, improving purity and reducing energy consumption during extraction [5]. Group 2: Market and Application - Spermidine is positioned to drive multiple billion-dollar industries, with products in the food sector entering trial production and clinical trials for cardiovascular disease prevention underway in the pharmaceutical sector [7]. - A report from McKinsey Global Institute indicates that 60% of industrial products could be manufactured using biotechnology, with synthetic biology expected to generate $2-4 trillion in direct economic benefits annually between 2030 and 2040 [7]. Group 3: Policy and Industry Collaboration - Chengdu has emerged as a hub for synthetic biology, with various local governments implementing supportive policies, facilitating the transition from technology to market applications [8]. - The collaboration between universities and enterprises is crucial for addressing real market needs, ensuring that research is aligned with practical applications [9].